Drug research

SPN-810

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as molindone

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Phase 2a Study of Safety and Tolerability of SPN-810 in Children With ADHD and Persistent Serious Conduct ProblemsNCT00626236	SUPN	Phase 2	Completed	2009-09-23Actual
Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD TreatmentNCT03597503	SUPN	Phase 3	Terminated	2020-01-22Actual
Exploratory fMRI Study on the Treatment for Impulsive Aggression in Children With ADHDNCT03638466	SUPN	Phase 2	Terminated	2019-11-07Actual
Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 4)NCT02691182	SUPN	Phase 3	Terminated	2021-05Actual

SUPNCompletedPrimary completion: 2009-09-23 · Actual

Trial details

SUPNTerminatedPrimary completion: 2020-01-22 · Actual

Trial details

SUPNTerminatedPrimary completion: 2019-11-07 · Actual

Trial details

SUPNTerminatedPrimary completion: 2021-05 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.